Immunoprecipitation of tumor associated ctDNA fragments for novel lung cancer liquid biopsy

D. PAMART, J.V. TURATZINE, T. BYGOTT, B. CUVELIER, M. HERZOG and J. MICALLEF
R&D Department, Belgie Volition SRL, Isnes, Belgium

Author Contact: d.pamart@volition.com; j.micallef@volition.com

Introduction

The main issue all tumor associated cfDNA assays have is a high background of normal cfDNA of near identical sequences. This issue is greatest in stage III cancer patients that tend to have plasma that is ~99.9% background normal cfDNA. Currently, the basis of cfDNA analysis consists of extracting and sequencing all plasma cfDNA including background. In silico comprehensive bioinformatic analysis of sequence data is used to combat the low detection levels of ctDNA.

A better solution could be to identify tumor associated cfDNA fragment sequences after physically isolation from normal cfDNA fragments with the same sequence based on nucleoprotein structure using wet chemistry.

We have developed a new physical cfDNA isolation method which separates specific circulating nucleoprotein - DNA structures from the typical cfDNA background with same sequence. Our method, based on TF ChiP-seq with CCCTC-binding factor protein (CTCF) as target, allows physical cfDNA fragment isolation from total cfDNA background in circulation in plasma. (Figure 1)

The method combines 2 elements:
1. Identification of nucleoprotein structures in which the combination of protein and nucleic acid sequence occurs exclusively in the circulation of cancer patients
2. Physical isolation and detection of those chromatin fragments from plasma

Using a novel biomarker discovery method, we identified a magnitude of gain of occupancy sequences characterized by CTCF binding site sequences that were present in the CTCF plasma isolates of cancer subjects but absent from those subjects without cancer. We considered these sequences to be tumor specific.

We believed that any DNA fragment containing a cancer associated CTCF gain of occupancy compared to control must be tumor associated.

Declaration of Interest

D Pamart is an employee of Volition.

D. PAMART

Proof-of-concept: Isolation of CTCF-cfDNA nucleoproteins from plasma of AML patients

Our first POC was performed on acute myeloid leukemia (AML) patients as they were considered to have high ctDNA in circulation. We isolated CTCF-cfDNA complexes from plasma with magnetic beads coated with anti-CTCF antibodies. Immunoprecipitated cfDNA was then extracted, amplified and sequenced on an Illumina platform. Frequency analysis plots proved the presence of a short DNA peak (35-100bp) in samples with high nucleosome/DNA levels (Figure 2a). Normalized coverage of CTCF binding site loci showed a high level of small 35-100bp cfDNA fragments but an absence of nucleosome sized fragments for all samples including healthy samples (Figure 2b). V-plots demonstrate that the CTCF binding sequences were located centrally within CTCF bound cfDNA fragments (Figure 2c).

We identified 29 CTCF-biding site sequences present in the ChiP isolate from cancer patients that were absent from other patients. Specific qPCR assays developed to these sequences showed good performance for AML cancer detection with 1-qPCR assay: Sensitivity 61%, Specificity 98% and with 2-qPCR assays: Sensitivity 74%, Specificity 96%.

Application to Lung Cancer

We reproduced our method using samples from 10 lung cancer patients. The CTCF-cfDNA was isolated from plasma by immunoprecipitation and after Next Generation Sequencing, the normalized coverage showed the presence of CTCF DNA binding site on DNA short fragment. This presence is specific to the CTCF DNA complex immunoprecipitation and is not present with unspecific antibody immunoprecipitation (figure 3a). Using a 3-qPCR assay based on an AML model we detected lung cancer (all stages):

Sensitivity: 42%, Specificity: 98%

We found 113 candidate CTCF-CfDNA binding sites selectively present in plasma samples of lung cancer patients (figure 3b). These sites have a False Discovery Rate < 0.05, with a p-value <0.05. We will develop PCR assays for selected candidates.

Conclusions

We have isolated cancer associated cfDNA from normal cfDNA of the same sequence by wet chemistry for detection by simple PCR. This strategy provides access to an entirely new class of hitherto unknown potential plasma biomarkers accessible to analysis without NGS.

We have demonstrated a novel cfDNA-analysis technology that may provide the basis of rapid, low cost detection of early-stage cancer.

This could be an automated liquid biopsy method, as the first step is a basic immunoprecipitation assay, and the second step uses qPCR.

This method was worked up using haemaglobin cancer samples; the biomarkers tested also gave positive results for lung cancer. The full potential of this method may allow tumor cell of origin analysis in the future.

We are currently investigating using lung cancer models rather than an AML model with the objective to further improve the sensitivity and specificity profiles.

Authors Contact: d.pamart@volition.com; j.micallef@volition.com